Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

BACKGROUND: The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, extending...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Commun (Lond)
Hauptverfasser: Oh, Sung Yong, Kim, Won Seog, Kim, Jin Seok, Kim, Seok Jin, Yoon, Dok Hyun, Yang, Deok-Hwan, Lee, Won Sik, Kim, Hyo Jung, Yhim, Ho-Young, Jeong, Seong Hyun, Won, Jong Ho, Lee, Suee, Kong, Jee Hyun, Lim, Sung-Nam, Ji, Jun Ho, Kwon, Kyung A., Lee, Gyeong-Won, Lee, Jae Hoon, Lee, Ho Sup, Shin, Ho-Jin, Suh, Cheolwon
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2019
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6796378/
https://ncbi.nlm.nih.gov/pubmed/31619290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-019-0403-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge